Piedmont Lithium

Phase A — Understand the business

Lens 1 · Company Overview

Elevra Lithium is a hard-rock (spodumene) lithium miner and aspiring integrated producer built from two complementary halves: Sayona's operating asset base and Piedmont's North American development pipeline plus its US commercial relationships.

Pre-merger Piedmont (the half on our shelf): "a U.S.-based, development-stage company advancing a multi-asset, integrated lithium business… We plan to supply lithium hydroxide to the electric vehicle and battery manufacturing supply chains in North America by processing spodumene concentrate produced from assets we own or in which we have an economic interest". Incorporated in Delaware 3 Dec 2020; HQ Belmont, NC. Its portfolio: wholly-owned Carolina Lithium (proposed integrated ore-to-hydroxide project, Gaston County NC), a 25% economic interest in the operating NAL mine (Quebec, via Sayona Quebec), an interest in Atlantic Lithium's Ewoyaa (Ghana), the Tennessee Lithium project, and Killick/Vinland Lithium (Newfoundland).

Post-merger Elevra: the operating heart is NAL in Québec — one of North America's few producing hard-rock lithium mines — now 100%-owned. Around it sits a staged growth pipeline (NAL expansion → Carolina Lithium) and, as of 2026, a deliberately narrowed footprint: Elevra agreed in May 2026 to sell its Ewoyaa (Ghana) interest to Zhejiang Huayou Cobalt for ~US$71M cash to focus on North American assets.

How it makes money: it mines and sells spodumene concentrate (SC6, ~6% Li₂O) to converters, priced on market-based mechanisms tied to the spodumene/lithium-chemical price. It is not yet an integrated lithium-hydroxide producer — that (Carolina) is the long-dated option, not the current cash engine.

Contract structure / key terms: Piedmont's legacy offtake with Sayona Quebec entitled it to "the greater of 113,000 dmt per year or 50% of annual spodumene concentrate production… subject to a price floor of $500 per dmt and a price ceiling of $900 per dmt for SC6, life-of-mine". Downstream, Piedmont resold under multi-year, market-priced offtakes to Tesla (125,000 dmt through Sept 2026) and LG Chem (200,000 dmt through ~Q2 2028 or upon delivery). Post-merger these become internal/legacy arrangements — the $500 floor/$900 ceiling is now an intra-company legacy term rather than a constraint on Elevra as owner, and Elevra now realises spot FOB pricing (US$998/dmt in the Dec-2025 quarter) directly.

Lens 2 · Supply Chain

Name-by-name map (upstream → company → end market):

• Orebody / mine: North American Lithium (NAL), Abitibi region, Québec — the producing asset. Restarted March 2023, reached steady-state June 2024. Record 2024 quarterly output 40,439 / 49,660 / 52,141 dmt; ~101,794 dmt produced in H1 2025.
• Prior JV parents: Sayona Mining (75%) + Piedmont (25%) via Sayona Quebec Inc. → now unified under Elevra.
• Processing / product: spodumene concentrate SC6 (~6% Li₂O), a dry metric tonne (dmt) commodity. Elevra does not yet operate a conversion (hydroxide/carbonate) plant — the chemical-conversion step is done by customers.
• Logistics chokepoint: NAL is inland Québec — concentrate moves by rail/road to port, then bulk shipping to converters (predominantly China). Sales are shipping-schedule-dependent (Elevra explicitly caveats sales guidance "subject to the shipping schedule being met").
• End customers (Piedmont-era, market-priced): Tesla, LG Chem (also a ~5% Elevra/Piedmont shareholder — it took 1,096,535 Piedmont shares in exchange for an offtake), plus a rotating book of third-party converters. Elevra's second-half-2024 "commercial strategy" used lithium futures markets to manage price.
• Single-source / chokepoint risks: NAL is effectively the whole company's revenue today — a single mine, single orebody, single jurisdiction. That is the dominant chokepoint. The Dec-2025 grade/iron wobble (below) shows how a single-asset producer is exposed to ore-body variability.

Named chain (compact): NAL orebody (Québec) → Elevra concentrator (SC6) → rail/port/bulk ship → converters (China + Tesla/LG Chem legacy offtakes) → cathode → EV/ESS cells.

Lens 3 · Competitive Advantages (moats)

Honest read: a hard-rock lithium miner has a thin, commodity moat, and Elevra is no exception. What durable edges exist:

1. Jurisdiction / policy tailwind. NAL (Canada) and Carolina (US) are IRA/USMCA-aligned, non-China supply — genuinely scarce and strategically valued by US OEMs and policymakers. This is Elevra's most real moat: Western battery makers structurally need ex-China lithium units, and there are few operating hard-rock mines in North America. Piedmont framed itself as supporting "U.S. and global energy security".
2. An operating asset, not a promise. Post-merger Elevra actually produces (~180–190k dmt guided FY26), which separates it from the large field of pre-revenue lithium juniors. Producing beats permitting.
3. Scale + balance sheet. The merger created a top-tier hard-rock platform with net cash (US$58.7M, Mar-2026 qtr), no secured debt, and a fully-funded NAL Stage-1 expansion. In a capital-starved sector that has spent 2023–25 curtailing, a funded producer has optionality.
4. Cost position (contested). FY26 unit operating cost guidance US$860–880/dmt. That is mid-cost, not low-cost — respectable at $1,800/t spodumene, loss-making at sub-$800/t. No structural cost moat.

Bargaining power: low as a price-taker on concentrate (SC6 is a fungible commodity priced off China). The offtakes to Tesla/LG Chem give some demand security but all pricing is market-based — no take-or-pay premium. Who needs whom more? At $2,000/t spodumene, converters need units; at $600/t, Elevra needs buyers. Power oscillates with the cycle — the opposite of a moat.

Lens 4 · Segments

segments.csv is empty (headers only) — no compiled segment data. Effectively the business is one segment (spodumene concentrate) from one asset (NAL), so segment breakdown ≈ consolidated revenue.

• Product: 100% spodumene concentrate. Piedmont FY2024: "All revenue was generated from sales of spodumene concentrate produced at NAL".
• Geography: production Québec; sales predominantly to China-based converters plus contracted Tesla/LG Chem volumes.
• Trend: volume up sharply, price down then up. Piedmont sold ~43,300 dmt (2023) → ~116,700 dmt (2024) → ~47,200 dmt in H1 2025. Elevra FY26 guides ~180–190k dmt combined-entity. The story is a volume ramp riding a violent price cycle — 2024 revenue rose 150.8% on 169.5% volume growth despite falling prices; 2026 revenue is rising on volume and recovering price.

The future segment story is integration: if Carolina Lithium is built, a second "lithium hydroxide" segment appears at a higher margin. Today that is optionality, not a segment.

---

Phase B — Measure performance

Lens 5 · Earnings Result

Two vantage points — the last standalone Piedmont print (on-shelf, ) and the live Elevra print .

Piedmont, Q2 2025 (last standalone 10-Q):

• Revenue $11.857M (Q2), down from $13.227M a year earlier; H1 2025 revenue $31.853M (+19.6% YoY on +60% volume, offset by price collapse).
• Gross loss $(1.632)M in Q2 — costs of sales ($13.489M) exceeded revenue. The mine was selling below cost at the trough.
• Loss from operations $(9.597)M (Q2); H1 $(21.452)M.
• Net loss $(9.738)M, $(0.44)/share (Q2); H1 net loss $(25.369)M, $(1.16)/share on ~21.9M weighted shares.
• FY2024 full year: revenue $99.9M (+150.8%), net loss $(64.761)M.
• Balance sheet (30 Jun 2025): cash $56.074M (down from $87.840M at YE2024 — heavy burn), total assets $318.5M, equity method investments $74.1M, advances to affiliates $42.0M, total liabilities only $40.9M, equity $277.6M, accumulated deficit $(216.974)M against $499.2M paid-in capital. A company that had raised ~$0.5B and burned nearly half of it into an accumulated deficit.

Elevra, FY2026 (live):

• Record quarterly revenue US$81M (+22% QoQ) in the Mar-2026 quarter; YTD revenue US$167M (+68% YoY).
• Dec-2025 quarter: 66,016 dmt sold at avg realised FOB US$998/dmt; NAL operating profit US$12M — i.e. the asset flipped from loss-making (Piedmont Q2-25) to profitable as price recovered.
• Net cash US$58.7M (Mar-2026 qtr, up from $26.4M Dec-2025); cash US$113.0M; no secured debt; prepayment facility US$54.3M.
• Consensus: first-ever profit — analysts model ~US$106.7M net profit for 2026 and ~US$222M revenue.
• Guidance cut (Jan 2026): FY26 spodumene production from 195,000+ to 180,000–190,000 dmt after Dec-2025 recovery problems (below).
• Market reaction: the equity has re-rated +426% over the trailing year — the market has already paid up hard for the recovery.

Unusual vs history: the entire complexion changed — a chronically loss-making minority-JV development company became a net-cash, cash-generative, ~$1B producer in under a year, driven ~90% by the lithium price and the merger, not by idiosyncratic execution.

Lens 6 · Earnings Calls (sentiment trend)

transcripts/ is empty — no compiled calls. From web coverage of the last few Elevra quarterly reports and the Q2-FY26 call:

• Focus has shifted from "close the merger / integrate" (H2 2025) → "disciplined, funded, staged growth" (2026): NAL Stage-1 expansion, Carolina permitting progress, Ewoyaa divestment, balance-sheet strength.
• Recurring phrases: "fully funded," "staged growth strategy," "capital efficiency / reduce execution risk," "record revenue," "positive cash flow," "injury-free."
• What they stopped saying: the survival/liquidity language that pervaded Piedmont's 2024–25 filings ("assumptions that may prove to be wrong… our operating plan may change… lithium pricing" ). The tone moved from defensive/going-concern-adjacent to constructive/growth, tracking the price.
• Honesty check: management cut guidance in Jan 2026 and named the cause plainly (lower recoveries from lower grades / higher iron), rather than burying it — a modest positive credibility signal.

Lens 7 · Comps

Peer set: global hard-rock and integrated lithium producers. Multiples are, dated; where I cannot source one I write n/a rather than fabricate.

Read: trailing multiples across the sector are meaningless (EBITDA was near zero at the trough — hence Pilbara's 3,374x and Liontown's negative). The sector trades on forward, recovery EBITDA. On the one clean cross-sectional metric available, Elevra's P/S (~10.9x) is below the peer average (~19.7x) — genuinely cheaper than ALB/SQM on sales, reflecting its smaller scale, single-asset concentration, and lack of downstream chemical margin. Elevra's own fwd EV/Sales ≈ 4.3–4.6x ]. A producer, not a converter — so a discount to the integrated majors is correct, not an anomaly.

Lens 8 · Stock-Price Catalysts (last ~5y)

Pattern of >5% moves for PLL→ELVR:

• 2021–22 lithium mania: PLL ran with the whole complex as spodumene/carbonate spiked to records — pure commodity beta.
• 2022 Tesla offtake / Carolina permitting headlines: single-customer and single-permit news moved the stock disproportionately (small float, ~20M shares).
• 2023–24 lithium crash: PLL fell ~80%+ with spodumene from ~$8,000/t to ~$800/t; repeated dilutive raises (e.g. Nov-2024 private placement, ~$24.6M for 2.38M shares ) were negative catalysts.
• Nov 2024: Sayona merger announcement — a strategic de-risking event.
• Aug 2025: merger close → PLL delists, becomes ELVR/ELV.
• H2 2025 – H1 2026: the +426% melt-up as spodumene reclaimed >$2,000/t; ESS demand (+117% YoY in Q1-26) and the Zimbabwe export ban (~7% of supply) were the macro catalysts, not company-specific execution.

What the tape says: this name is ~90% a lithium-price expression. It reacts to spodumene/carbonate prints, supply-shock headlines (Zimbabwe, CATL/Chinese curtailments), and dilution — far more than to its own operating beats. Buy/sell it as commodity beta with a single-asset tilt.

---

Phase C — Judge people & books

Lens 9 · Management

Post-merger leadership is a Sayona-led operating team over a Piedmont-heavy board:

• CEO: Lucas Dow (ex-Sayona MD/CEO since Jul 2024). An operator running the producing asset base — appropriate for a company whose value now rests on running NAL well, not on capital-markets storytelling.
• Chair: Dawne Hickton (Piedmont designee).
• Keith Phillips (Piedmont's CEO since Jul 2017, age 64, a 30-year Wall Street dealmaker) stepped back to strategic advisor and retired from the executive role. Reads as the right handoff — Phillips was a promoter/financier archetype (he assembled the asset portfolio and the offtakes and did the merger); the company now needs a mine operator, which Dow is.
• Board: 8 directors, 4 ex-Sayona / 4 ex-Piedmont — a balanced merger-of-equals board (Dow, James Brown, Allan Buckler, Laurie Lefcourt; Hickton, Christina Alvord, Jeff Armstrong, Jorge Beristain).

Track record: Sayona actually restarted NAL and took it to steady-state (2023–24) — real operating delivery. Piedmont's record is more mixed: it assembled a global option portfolio and marquee offtakes but never built its flagship (Carolina still unbuilt) and serially diluted shareholders through the downturn.

Skin in the game: insider-transactions.csv not present. LG Chem holds ~5% (strategic, from the offtake-for-equity deal). No evidence of large founder/insider ownership — this is a professionally-managed company, not a founder-owner vehicle.

Capital allocation: the recent moves are rational and disciplined — merge to gain scale/control of NAL; divest non-core Ewoyaa for ~US$71M to fund North America; keep the balance sheet net cash / unlevered; fund the NAL expansion from a strength position. That is a marked improvement over the prior dilute-to-survive pattern. Red flags: the history of dilution at low prices and the related-party density of the old structure (Piedmont buying its own JV's offtake, sitting on the Sayona Quebec board) — largely resolved by the merger, but a reminder the governance was previously tangled.

Lens 10 · Forensic Red Flags

Grounded in the Piedmont filings (the last audited standalone set) + Elevra web disclosure:

• Equity-method complexity (biggest historical flag). Piedmont's accounts were riddled with equity-method investments and affiliate advances: "Loss from equity method investments" of $(6.074)M H1-25; advances to affiliates $42.0M; equity-method investments $74.1M. Earnings quality was muddied by mark-to-market on Sayona/Atlantic Lithium stakes — e.g. a $(17.215)M loss on the sale of Sayona shares and a $2.2M impairment on the Sayona investment. The merger consolidates these, which improves transparency going forward but means historical comparability is poor.
• Cash flow vs earnings. Operating activities used $21.3M in H1-25 vs a $25.4M net loss — losses were largely cash, not non-cash accruals. No aggressive revenue-recognition signal; revenue is provisionally priced (e.g. volumes "with an average provisional price of $660 per dmt… subject to final pricing" ), a normal commodity mechanism but one that adds mark-to-market noise.
• SBC: modest and declining ($1.873M H1-25 vs $4.640M H1-24) — not flattering non-GAAP.
• Going-concern / liquidity: management asserted liquidity "sufficient… for the twelve months following" but explicitly caveated on lithium pricing. Pre-merger, this was a genuinely stretched balance sheet ($56M cash, fully-drawn $25M facility). Post-merger Elevra is net cash — the flag is resolved.
• Foreign-issuer reporting change: Elevra now files 20-F/6-K as an Australian FPI — less frequent, less granular than 10-Q quarterly detail. A disclosure-quality step-down for US investors to note.

Regulatory findings (required sub-section):

• SEC Litigation Releases: None. "No LR found for this company".
• SEC AAERs: None. "No AAER found".
• Item 3 — Legal Proceedings (Piedmont FY2024 10-K): no material litigation disclosed of note; the substantive legal/permitting risk is local zoning/permitting opposition to Carolina Lithium (Gaston County), a recurring risk-factor theme rather than an enforcement action.
• Non-SEC enforcement (web): no material FTC/DOJ/EPA enforcement, consent decree, or penalty surfaced for Piedmont/Elevra as of this date.
• Net: No material regulatory or accounting-enforcement findings — verified via SEC EDGAR EFTS (LR + AAER), 10-K Item 3, and web search as of 2026-07-10. The real "red flags" are structural (single-asset concentration, commodity cyclicality, historical dilution), not forensic.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection

No forecast.ts create in watchlist/unattended mode (per skill + task instruction). EPS scaffold for Elevra (fiscal year ~June; figures US$, all **** built off **** consensus and lithium-price scenarios). Elevra shares ≈ 12M ADRs (ELVR) implied by ~$1.08B mkt cap ÷ ~$89 — but the ASX line and ADR ratio make per-share EPS noisy, so I project net income and note EPS is ratio-dependent.

Base (spodumene ~$1,600–1,900/t through 2026, easing 2027):

• 2026 revenue ~US$222M, net income ~US$100–107M — first profit, driven by price × ~180–190k dmt.
• 2027: volumes +15–20% as NAL Stage-1 completes (mid-CY27) but price normalises toward ~$1,300/t → net income ~US$70–110M.
• 2028: Stage-1 full-year + possible Carolina FID; net income ~US$80–140M, wide band, price-dominated.

Bull (spodumene sustains >$2,200/t; deficit deepens): 2026 net income $130–160M; 2027–28 materially higher; Carolina becomes financeable — multi-hundred-million earnings power by decade-end.

Bear (spodumene relapses to <$900/t on Chinese/African supply): NAL near breakeven at ~$860–880/dmt cost; 2026 profit evaporates back toward $0–20M, 2027 potentially loss-making again; expansion capex looks premature. This is the realistic downside — lithium has done it twice this decade.

Key inputs (labelled): unit cost $860–880/dmt; FY26 volume 180–190k dmt; price the single dominant swing factor; net-cash balance sheet removes solvency risk from the bear case.

Lens 12 · Bull vs Bear

Bull case. A scaled, net-cash, fully-funded North American hard-rock producer at the exact moment the lithium market flips from surplus to deficit (ESS demand +117% YoY, Zimbabwe export ban, three years of curtailed supply). NAL is a rare operating ex-China mine; Stage-1 expansion adds low-risk volume; the Ewoyaa sale sharpens focus and adds ~$71M; Carolina Lithium is a free integration option on US policy support. On P/S (~10.9x vs 19.7x peers) it screens cheaper than the majors. If spodumene holds >$1,800/t, Elevra compounds cash and Carolina gets built — a genuine multi-year re-rate.

Bear case (permanent-impairment risks). (1) Commodity cyclicality — lithium is violently mean-reverting; a supply response (Africa, China lepidolite, brine) could halve prices and push NAL back to breakeven, as in 2024–25. (2) Single-asset concentration — NAL is the company; the Dec-2025 grade/iron recovery miss shows one orebody's variability can cut group guidance ~7% overnight. (3) Expectations already priced — the stock is up ~5x off the bottom; consensus already models first profit and further price gains, so the easy mispricing is gone. Pre-mortem (18 months out, thesis broke): spodumene relapsed to ~$900/t as Zimbabwe/African tonnes returned and the ESS spike normalised; NAL's high-iron zones persisted, keeping costs near price; Elevra spent expansion capex into a softening market and the stock round-tripped half its gains. Multiples too high? Not egregiously on P/S, but the forward case bakes in a sustained high lithium price — the risk is the denominator (price), not the multiple. Contrarian view the market is missing: the market is treating the 2026 spike as a new plateau; single-asset hard-rock producers are the highest-beta way to be wrong if it's just another cycle head-fake.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull:

• What structurally breaks it: a lithium price relapse. Full stop. Elevra sells one undifferentiated commodity from one mine; at <$900/t spodumene the P&L returns to the Piedmont-Q2-2025 world of gross losses. The $860–880/dmt cost base is not low enough to be cycle-proof.
• Revenue concentration: ~100% NAL / spodumene. Any operational hit (the Dec-2025 recovery miss, a mill outage, a Québec winter logistics freeze, a rail disruption) hits all revenue.
• Why the moat is weaker than bulls think: "ex-China, IRA-aligned" is a policy moat, not a cost moat — and policy can shift (IRA rollback risk, tariff regimes). Converters buy the cheapest compliant tonne; Elevra has no pricing premium.
• Most dangerous competitor bulls underrate: African supply (Zimbabwe once its ban lifts / is circumvented, plus Mali, DRC) and Chinese lepidolite — the low-cost swing tonnes that crushed prices in 2023–24 and can do it again. Also the integrated majors (Albemarle, SQM, Pilbara) who can outspend Elevra on downstream conversion where the real margin sits.
• Worst capital-allocation history: Piedmont's serial dilution at the lows and a tangled related-party JV structure. New team looks better, but the culture of raising into weakness is a risk if the cycle turns.
• Assumptions that must hold for today's price: sustained spodumene >$1,500/t, NAL recoveries normalising back to LOM grade, expansion delivered on time/budget, and no major new low-cost supply. That's four things, all outside management's control.
• If growth disappoints 20–30%: on a price-driven model, a 25% lower realised price roughly erases the consensus profit and the stock — up 5x — has a long way to fall. Downside asymmetry is real after the run.
• Single scenario that permanently impairs: a structural oversupply (Africa + China + brine all ramping) that parks spodumene at ~$700–900/t for 2–3 years, turning NAL cash-neutral and stranding Carolina — plausible given lithium's history, maybe 25–35% over 2–3 years.

Lens 14 · Management Questions (ordered by information value)

1. At what realised spodumene price does NAL go cash-flow-negative at current costs, and what is your hedging/curtailment plan if we revisit sub-$900/t?
2. Is the Dec-2025 recovery/grade/iron problem fully resolved, or is high-iron ore a structural feature of NAL's remaining reserve — what's the LOM grade risk?
3. What is the standalone cost curve position of NAL (C1/AISC) versus African and Chinese lepidolite swing supply?
4. Post-Ewoyaa sale, what is the capital-allocation priority stack — NAL expansion vs Carolina FID vs buybacks vs balance-sheet — and the hurdle rate for each?
5. What are the real gating items and cost for a Carolina Lithium FID, and under what lithium-price deck does it clear?
6. How dependent is the equity story on US policy (IRA/45X, tariffs), and what's the plan if that support erodes?
7. What genuine cost synergies has the merger delivered vs underwritten, quantified?
8. With FPI (20-F/6-K) reporting, will you voluntarily provide quarterly detail comparable to the old 10-Q, or are US holders taking a disclosure step-down?
9. What is your through-cycle net-debt ceiling — will you commit to not diluting at depressed prices as the prior entity did?
10. What share of FY26 volume is contracted (Tesla/LG Chem legacy) vs spot, and how do those price mechanisms differ from spot FOB today?
11. Do you intend to move downstream into conversion (hydroxide) yourselves, or stay a concentrate seller — and why?
12. What is the reserve/resource life at NAL at current mining rates, and the exploration path to extend it?
13. How should investors think about the ASX/Nasdaq dual listing and ADR ratio — is a consolidation or single-line plan on the table?
14. What is the realistic Stage-1 expansion cost/schedule risk, and what de-risks mid-CY27 delivery?
15. What single operational metric should we hold you accountable to over the next four quarters?

---